Ethiopia: GMP compliant local drug and API sector would yield health and economic benefits

By Gareth Macdonald

- Last updated on GMT

Ethiopia aims to make first API by 2020
Ethiopia aims to make first API by 2020

Related tags Active ingredient

Ethiopia will start making its own APIs in 2020 according to the Government which says local manufacture will improve access to medicines, curb sale of counterfeits and promote innovation.

The Ethiopian Government published its Pharmaceutical Manufacturing Sector Strategy and Action Plan​ (2015 -2025) yesterday, explaining that the aim is to make the country’s drug manufacturing sector fully good manufacturing practices (GMP) compliant by 2025.

This will require a considerable effort as – according to the report – currently only two Ethiopian companies are GMP-compliant, although two more are about to acquire GMP certificates from the PIC/S.

But, despite the challenge, the rationale for improving standards is clear according to Prof Tsige Gebre-Mariam from Addis Ababa University’s School of Pharmacy.

There are major public health and economic benefits to be derived from local production of essential medicines and a thriving domestic pharmaceutical industry​” Gebre-Mariam told us.

He cited improved access to medicines, enhanced protection against counterfeits and reduced reliance on imports among the benefits of local production, explaining that at present only 20% of medicines used in the country are produced locally.

Ethiopia aspires to be self-reliant in essential medicines and this can be achieved by developing a viable and value-added manufacturing industry for medicines​” Gebre-Mariam said, adding that the approach will create jobs and promote skills development.

Local producers will also be better placed to meet specific local demand according to Gebre-Mariam, who said: “The disease burden in Ethiopia and other developing countries is not any more limited to communicable diseases; non-communicable diseases are on the rise.”

API manufacture

The Government's strategy will involve producing both active pharmaceutical ingredients (APIs) and finished dosage forms with efforts being tailored to meet the country’s needs.

Ethiopia is planning to produce medicines for neglected tropical diseases, which apparently are not the problem of the US and Europe​” Gebre-Mariam said.

He predicted that at least one local manufacturer would be making APIs by 2020 and suggested as many as four will be producing a limited number of drug actives by 2025.

Gebre-Mariam also expects – after sufficient production capacity and R&D infrastructure is established - that Ethiopian API and drug firms will supply other markets.

All market aspirations and success are based on market law- competitiveness… Ethiopia will explore the niche areas as it is endowed with huge potential​” he said, citing the country’s soil and plant flora as a diverse untapped resource for potential new medicines.

Related news

Show more

Related products

show more

Life Cycle Extension: A Molecule’s Full Potential

Life Cycle Extension: A Molecule’s Full Potential

Piramal Pharma Solutions | 16-Feb-2023 | Technical / White Paper

Winning approval for a new molecular entity is just a staging post on the journey of a drug. To maximize the benefits of a therapy, drugmakers need to...

Understanding the hidden value of quality

Understanding the hidden value of quality

Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | Technical / White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.



Indena | 25-Oct-2022 | Technical / White Paper

Indena is well known in the space of naturally derived molecules, with a know-how developed over its one hundred year history. At the same time, the company...

Related suppliers

Follow us


View more